Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats.
BACKGROUND
The development of analgesic tolerance following chronic morphine administration can be a significant clinical problem. Preclinical studies demonstrate that chronic morphine administration induces spinal gliosis and that inhibition of gliosis prevents the development of analgesic tolerance to opioids. Many studies have also demonstrated that ultra-low doses of naltrexone inhibit the development of spinal morphine antinociceptive tolerance and clinical studies demonstrate that it has opioid sparing effects. In this study we demonstrate that ultra-low dose naltrexone attenuates glial activation, which may contribute to its effects on attenuating tolerance.


RESULTS
Spinal cord sections from rats administered chronic morphine showed significantly increased immuno-labelling of astrocytes and microglia compared to saline controls, consistent with activation. 3-D images of astrocytes from animals administered chronic morphine had significantly larger volumes compared to saline controls. Co-injection of ultra-low dose naltrexone attenuated this increase in volume, but the mean volume differed from saline-treated and naltrexone-treated controls. Astrocyte and microglial immuno-labelling was attenuated in rats co-administered ultra-low dose naltrexone compared to morphine-treated rats and did not differ from controls. Glial activation, as characterized by immunohistochemical labelling and cell size, was positively correlated with the extent of tolerance developed. Morphine-induced glial activation was not due to cell proliferation as there was no difference observed in the total number of glial cells following chronic morphine treatment compared to controls. Furthermore, using 5-bromo-2-deoxyuridine, no increase in spinal cord cell proliferation was observed following chronic morphine administration.


CONCLUSIONS
Taken together, we demonstrate a positive correlation between the prevention of analgesic tolerance and the inhibition of spinal gliosis by treatment with ultra-low dose naltrexone. This research provides further validation for using ultra-low dose opioid receptor antagonists in the treatment of various pain syndromes.
Mattioli
Theresa-Alexandra M
TA
Department of Pharmacology & Toxicology, Queen's University, Kingston, Ontario, K7L 3N6, Canada. 6tam1@queensu.ca
Milne
Brian
B
Cahill
Catherine M
CM
D000818:Animals; D004361:Drug Tolerance; D005911:Gliosis / Q000139:chemically induced* / Q000188:drug therapy*; D021621:Imaging, Three-Dimensional; D007150:Immunohistochemistry; D008297:Male; D009020:Morphine / Q000009:adverse effects* / Q000627:therapeutic use; D009271:Naltrexone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000187:drug effects / Q000378:metabolism
D009292:Narcotic Antagonists; D009271:Naltrexone; D009020:Morphine
Eur J Pain. 1997;1(2):115-22
15102412
J Pain. 2005 Jun;6(6):392-9
15943961
J Neurosci. 1994 Apr;14(4):2301-12
7908958
Pain. 1988 Apr;33(1):11-23
2454440
Neuropharmacology. 1991 Nov;30(11):1233-9
1663598
Eur J Pharmacol. 2000 Oct 20;406(3):391-401
11040346
J Pharmacol Exp Ther. 1995 May;273(2):887-94
7752094
Clin Pharmacol Ther. 2008 Jan;83(1):144-52
17568402
Brain Res. 1995 Jul 24;686(2):239-48
7583289
Br J Pharmacol. 2000 Nov;131(5):875-84
11053206
Brain Res. 1999 May 22;829(1-2):209-21
10350552
Neuroscience. 2005;135(1):247-61
16084657
Pain Res Manag. 2009 Mar-Apr;14(2):103-8
19532850
Eur J Neurosci. 2004 Jan;19(2):479-84
14725643
Brain Res. 1997 May 23;757(2):176-90
9200746
Science. 1991 Jan 4;251(4989):85-7
1824728
Glia. 1998 Mar;22(3):249-59
9482211
Neuropsychopharmacology. 2004 Feb;29(2):327-34
14532913
Neurochem Res. 1990 Nov;15(11):1123-6
1982460
Neuroscience. 2009 Apr 10;159(4):1244-56
19409222
J Neurosci. 2003 May 15;23(10):4017-22
12764087
Trends Neurosci. 1996 Aug;19(8):312-8
8843599
Brain Res. 2006 Jan 19;1069(1):235-43
16403466
Pharmacol Biochem Behav. 1988 Mar;29(3):595-99
3362954
J Neurosci. 2002 Nov 15;22(22):9980-9
12427855
Pain Physician. 2008 Mar;11(2 Suppl):S105-20
18443635
ScientificWorldJournal. 2007 Nov 02;7:98-111
17982582
Brain Res. 1997 Dec 19;778(2):367-80
9459554
Proc Natl Acad Sci U S A. 1981 Jul;78(7):4185-9
6117072
Brain Behav Immun. 2007 Feb;21(2):131-46
17175134
J Pharmacol Exp Ther. 2005 Jun;313(3):1239-47
15743926
J Pain. 2006 Dec;7(12):937-46
17157780
Mol Pain. 2009 Sep 22;5:53
19772627
Pain. 2003 Aug;104(3):655-664
12927638
Mol Pain. 2007 Mar 12;3:7
17352824
Nature. 1996 Oct 31;383(6603):819-23
8893006
Brain Res Mol Brain Res. 1995 Dec 28;34(2):209-20
8750824
Neurosci Res. 2001 Mar;39(3):281-6
11248367
J Pharmacol Exp Ther. 2003 Aug;306(2):624-30
12734393
Trends Pharmacol Sci. 1990 Feb;11(2):77-81
2156364
J Pain. 2008 Aug;9(8):700-13
18468954
PLoS One. 2008 Feb 06;3(2):e1554
18253501
J Pharmacol Exp Ther. 2002 Feb;300(2):588-96
11805221
J Pharmacol Exp Ther. 2001 Jun;297(3):1210-7
11356948
Glia. 2004 Jan 1;45(1):89-95
14648549
Eur J Neurosci. 2003 Sep;18(6):1572-83
14511336
Brain Res. 1991 Nov 22;565(1):1-7
1723019
J Pain Symptom Manage. 2000 Jan;19(1 Suppl):S7-11
10687332